STOK250117C12500
- 0.70
- +0.15+27.27%
Stoke Therapeutics Newsroom
Leerink Partners Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $24
Stoke Therapeutics Initiated at Buy by Chardan Capital
Stoke Therapeutics Price Target Announced at $24.00/Share by Chardan Capital
Stoke Therapeutics Analyst Ratings
Stoke Therapeutics: Promising Developments in Seizure Treatment Bolster Buy Rating
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $22
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
Analysts' Top Healthcare Picks: Stoke Therapeutics (STOK), Beam Therapeutics (BEAM)
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $29
CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $20
J.P. Morgan Maintains Stoke Therapeutics(STOK.US) With Hold Rating, Raises Target Price to $15
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $15 to $35
Analysts Conflicted on These Healthcare Names: AnaptysBio (ANAB), Stoke Therapeutics (STOK) and Immatics (IMTX)
Stoke Therapeutics' Zorevunersen Shows Promising Efficacy in Reducing Seizures and Improving Quality of Life, Justifying Buy Rating
Stoke Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Stoke Therapeutics Analyst Ratings
Leerink Partners Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Cuts Target Price to $18
TD Cowen Maintains Stoke Therapeutics(STOK.US) With Buy Rating
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $29
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35